LD 02GIFRO

Drug Profile

LD 02GIFRO

Alternative Names: LD02GIFRO

Latest Information Update: 28 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LG Life Sciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Postoperative ileus

Most Recent Events

  • 28 Aug 2015 Preclinical development is ongoing in China
  • 28 Aug 2015 No recent reports on development identified - Phase-II for Postoperative ileus in South Korea (unspecified route)
  • 31 Oct 2012 LG Life Sciences completes a phase II trial in Postoperative ileus in South Korea (NCT01624571)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top